scispace - formally typeset
A

Anat Mirelman

Researcher at Tel Aviv Sourasky Medical Center

Publications -  246
Citations -  12440

Anat Mirelman is an academic researcher from Tel Aviv Sourasky Medical Center. The author has contributed to research in topics: Medicine & Gait (human). The author has an hindex of 47, co-authored 208 publications receiving 9246 citations. Previous affiliations of Anat Mirelman include Harvard University & Ben-Gurion University of the Negev.

Papers
More filters
Journal ArticleDOI

The transition between turning and sitting in patients with Parkinson's disease: A wearable device detects an unexpected sequence of events.

TL;DR: Poorer postural and gait control are associated with the strategy choice and with the duration of concurrent performance of turning and sitting when patients with Parkinson's disease transition from turning to sitting.
Journal ArticleDOI

A Personalized Approach to Parkinson's Disease Patients Based on Founder Mutation Analysis.

TL;DR: It is believed that sufficient evidence has accumulated to warrant the initiation of personalized medicine in PD based on subjects genotype and examples for this reasoning are provided from observations of GBA and LRRK2 mutations carriers.
Journal ArticleDOI

Fall risk is associated with amplified functional connectivity of the central executive network in patients with Parkinson’s disease

TL;DR: Mediation analysis demonstrated that the relationships between caudate head gray matter volume and fall history and risk were mediated by increased connectivity within the central executive network, apparently via attentional changes.
Journal ArticleDOI

Prefrontal cortex activation during obstacle negotiation: What's the effect size and timing?

TL;DR: These findings are the first to show that the pattern of prefrontal activation depends on the nature of the obstacle, and during unanticipated obstacles the recruitment of the prefrontal cortex is faster and greater than during negotiating anticipated obstacles.
Journal ArticleDOI

Revisiting the non-Gaucher-GBA-E326K carrier state: Is it sufficient to increase Parkinson's disease risk?

TL;DR: A higher frequency of PD patients that carry two mutations is demonstrated, and an additive effect on risk and earlier AAO was proposed for carriers of LRRK2/mild-GBA double mutations, and these data support an oligogenic approach to PD genetics.